IGC Pharma targets commercial rollout of PRISM layer for Alzheimer’s risk assessment and cognitive monitoring
IGC Pharma launched PRISM to move its Alzheimer’s AI from risk prediction into deployable clinical and consumer workflows. Planning commercialization via B2B, B2B2C, online channels; targeting providers, memory clinics, drugmakers, trial sponsors, insurers. PRISM slated to support earlier risk stratification, longitudi